BIO 2009
Emory President James Wagner signs a research Memorandum of
Understanding between the Emory Vaccine Center and the
Australian Centre for Vaccine Development at the BIO 2009 International Convention.
Georgia Governor Sonny Perdue announced the new research collaboration, as well
as a new Emory Institute for Drug Discovery. Also pictured are the Hon. Stephen
Robertson MP, Queensland Minister for Trade, and Julie-Anne Tarr, General
Manager of the Queensland Institute of Medical Research.
The 2009 BIO International Convention, held May 18-21 at the Georgia World Congress Center in Atlanta, showcased Georgia's research universities, including Emory, through exhibits, presentations, announcements and press coverage.
News Stories
- Biotech Research to Make Mark Here
Atlanta Journal Constitution
May 19, 2009 - Emory starts drug discovery center
Atlanta Business Chronicle
May 19, 2009 - Bio fusion
Atlanta Business Chronicle
May 15, 2009 - Life sciences industry young, growing rapidly
Atlanta Business Chronicle
May 15, 2009 - Life's Work
Georgia Trend Magazine
May 2009 - Lifesaving Science (special section)
Sky Magazine
May 2009
Emory News Releases
- New Institute for Drug Discovery Announced (5/19/09)
- Emory, Australian Vaccine Centers Announce Alliance (5/19/09)
Emory Biomedical Research Centers and Institutes
Emory University and its Robert W. Woodruff Health Sciences Center include numerous biomedical research centers and institutes:
- the National Cancer Institute–designated Winship Cancer Institute;
- the Emory Vaccine Center, one of the largest academic vaccine centers in the world;
- the Yerkes National Primate Research Center, one of eight in the nation funded by the National Institutes of Health;
- the Emory Center for AIDS Research, which includes more than 120 scientists working on HIV/AIDS; and
- the Comprehensive Neurosciences Center.
Other major centers focus on predictive health, global health, clinical and translational research, influenza, drug discovery, heart and vascular disease, transplantation, nanotechnology, imaging, and informatics.
Research Funding
Edmund Waller,
Emory Winship Cancer Institute
Last year Emory researchers received $411 million in external research funding, including more than $250 million from the National Institutes of Health. (See: "Emory University Tops $400 Million in FY08 Research Funding," 10/10/08).
Technology Transfer & Startups
The Emory Office of Technology Transfer (OTT) partners with Emory faculty scientists to bring the results of biomedical research more rapidly to patients and the community through patenting, licensing and creation of new start-up companies.
Emory’s OTT has realized major licensing successes such as the Emory-discovered anti-AIDS drugs Emtriva and Epivir, taken by more than 94 percent of U.S. patients with HIV who are on antiviral therapy.
One of the leading AIDS vaccine candidates, discovered by Emory scientists at the Emory Vaccine Center and Yerkes National Primate Research Center, and colleagues at the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH), was licensed to Emory biotech start-up GeoVax, Inc., and currently is in Phase II clinical trials.
Emory has received more than $760 million in licensing revenues for its discoveries through technology transfer, including $540 million in 2005 from future royalty payments for Emtriva.
Forty-six start-up companies have resulted from licensing of Emory discoveries, including drugs, medical devices, diagnostics, and medical software. The most widely used drugs for HIV/AIDS, diagnostic tests for genetic disorders, drugs for cancer and hemophilia, a technology to improve angioplasty, and imaging software for diagnosing cardiovascular disease are among the many Emory discoveries now commercially available for patients and physicians.
Emory’s robust product pipeline includes more than 50 products in all stages of development and regulatory approval, with 27 having reached the marketplace and 12 more in human clinical trials. Since 2000, more than 170 patents have been executed on Emory technologies.
Emory and the Georgia Institute of Technology (Georgia Tech) share a joint biotechnology incubator, Emtech Bio, which houses five Emory biotech start-up companies:
In the most recent report from the Association of University Technology Managers, Emory ranked 16th nationally among universities in revenue received from commercializing research discoveries.
For more information about technology transfer, the production pipeline, start-up companies and technology available for licensing, see the web for OTT web site.
Research in the Woodruff Health Sciences Center
To find out more about research in the Woodruff Health Sciences Center, visit:
More Information
For more information, please contact Emory Health Sciences Communications at 404-727-5686, or Emory Office of Technology Transfer at 404-727-7218.
